Bonhoure et al. 8 reported that sustained SPHK1 overexpresion can render HL60 cells chemoresistant by decreasing the cellular ceramide level and that a novel SPHK1 inhibitor, F-12509a, could recover chemosensitivity. Considering the molecular target of chemotherapy, enzyme inhibitors are more practical than agents for enzyme activation (NSMase2 in our case). Inhibitor of SPHK1 is almost at the stage of clinical investigation. In the present study, we could analyze only one time point of patients (mostly at their first diagnosis before chemotherapy) and could not measure enzyme activities due to the paucity of samples. The measurement of SPHK1 gene expression and/or SPHK enzyme activity of each patient might be necessary to assess the efficacy of enzyme inhibitors in future clinical settings. Sequential analysis of the same patients will also add further information.
The localization and activation of enzymes are also important factors to determine the final cellular ceramide/S1P rheostat. SPHK1 was reportedly activated by phosphorylation by agonists and translocated to membranes. 2 Therefore, further analysis of enzyme activation is necessary to conclude firmly that sphingolipid metabolizing enzymes such as SPHK1 are a novel and promising molecular target for acute leukemia chemotherapy.
Taken together, this is, to our knowledge, the first report of a gene expression profile of major sphingolipid metabolizing enzymes of AL and MDS using quantitative RT-PCR, It documents the increase of SPHK1 gene expression in AL and RAEB-t and the decrease of NSMase2 gene expression in AL and RAEB, suggesting that sphingolipid metabolizing enzymes such as SPHK1 could be a novel target for the chemotherapy of AL. Cytogenetics is an important factor in hematologic disease classification and prognostication. However, accurate cytogenetic diagnosis depends on a number of parameters including overall mitotic index, the presence of dividing cells from the abnormal cell population, chromosome morphology and bandlength resolution. As a result, chromosome aberrations found in patients with leukemia may be missed or inaccurately interpreted when the banding resolution is at or below 400 bands per haploid set. In view of these well-recognized limitations, fluorescence in situ hybridization (FISH) has proven to be particularly useful for the characterization and identification of known or suspected chromosome aberrations in neoplastic studies. whereas the myeloid/lymphoid or mixed-lineage leukemia Letters to the Editor translocated to 1 (MLLT1) gene at 19p13.3 (formerly known as ENL), is rearranged frequently in patients with t(11;19) B-cell acute lymphoid leukemia. 3 However, rare acute myeloblastic leukemia (AML) or pediatric T-cell ALL (acute lymphoblastic leukemia) patients have been reported with the 19p13.3 breakpoint. 4 The mechanisms by which different patients with the same chromosome translocation and gene rearrangement can show a different tumor phenotype remain unknown.
Molecular characterization of t(11;19)-positive pediatric acute leukemia patients has shown that the majority (23 of 26) carry the MLLT1/MLL gene rearrangement, 4 suggesting that the 19p13.3 breakpoint may be restricted to B-cell ALL. Only two patients from that series, both with myeloid disease, had an ELL/MLL gene rearrangement, consistent with the relatively rare 19p13.1 breakpoint finding in pediatric leukemia patients. In contrast, 32 adult patients with t(11;19) acute myeloid leukemia, which are confirmed by conventional cytogenetics and MLL FISH but lacking confirmation of ELL or MLLT1 gene involvement, reported a 19p13.1 breakpoint, reflective of a probable ELL gene rearrangement. 5, 6 At the cytogenetic level of resolution, it is not always possible to clearly distinguish which breakpoint is involved in these translocations. The genes are separated by B12.3 Mb on the 19p-chromosome arm and the region has a paucity of landmark G-positive bands. Precise cytogenetic and readily available molecular classification may be necessary for appropriate chemotherapy regimens, especially in patients presenting with both myeloid and lymphoid phenotypic markers. Moreover, the question remains as to whether all adult t(11;19)-positive patients have an ELL gene rearrangement and whether those reported have been accurately classified. 7 To address this concern, we developed and validated a simple 'home brew' dual-color FISH assay using bacterial artificial chromosomes (BACs) to distinguish between ELL and MLLT1 gene rearrangements. The probes and assay were validated using a series of 'coded' residual specimens from 12 adult patients with confirmed t(11;19) leukemia identified from retrospective searches of the Sacred Heart Medical Center (SHMC), City of Hope National Medical Center (COHNMC) and Seattle Cancer Care Alliance (SCCA) cytogenetic databases. Institutional Review Board (IRB) consent was confirmed before study.
BAC clones were chosen from the UCSC and NCBI data bases (www.genome.ucsc.edu/cgi.bin/hgGateway and www.ncbi.nlm. nih.gov). BAC RP11 819E16 includes the MLLT1 gene (clone length 194 kb, gene length 70 kb) and BAC RP11 908B10 includes the ELL gene (clone length 209 kb, gene length 78 kb). ELL was directly labeled with Spectrum Orange (Vysis catalog no.; 30-803000) and MLLT1 with Spectrum Green (Vysis catalog no.; 30-803200) using a standard nick-translation protocol (Vysis nick translation kit, catalog no.; 32-811300); the probes were co-hybridized using standard FISH hybridization procedures. Interphase nuclei were scored for the number of green signals (G) and number of orange signals (O) with gain of an orange signal indicating an ELL gene rearrangement (3O2G signal pattern) (Figure 1, bottom right) , or gain of a green signal indicating an MLLT1L gene rearrangement (3G2O signal pattern) (Figure 1, bottom left) . In addition, each ELL/MLLT1 specimen was also independently evaluated using a commercially available dual-color MLL break-apart probe (Vysis, Catalog no.; 32-190083). As constructed, the 5 0 end of the MLL gene and upstream sequences are labeled in Spectrum Green and the 3 0 end of the MLL gene and downstream sequences are labeled in Spectrum Orange, with a slight probe overlap in the exons 6-8 region of the MLL gene, the common breakpoint cluster region (www.Vysis.com). MLL translocationpositive cells will show an abnormal 1O1G1Fusion signal pattern, indicating separation of one fusion signal into one orange and one green signal, whereas normal cells show two intact fusion signals.
Two independent laboratories (SHMC and COHNMC) evaluated the probe set to establish clinically valid cutoffs for the presence of disease. At SHMC, validation studies were performed using pooled bone marrow specimens from t(11;19)-negative patients. Five thousand interphase nuclei and 100 metaphases were analyzed for each probe's pattern; probe specificity was 100%, with a calculated sensitivity of greater than 97% for both loci, yielding a cutoff for disease (including plus
At the COHNMC, the ELL/MLLT1 probe set showed a threshold for negativity at p3% (sensitivity, 100 with 95% confidence limits of 54.1-100% and specificity, 100 with 95% confidence limits of 69.2-100%). The 11q23/MLL probe (Vysis Inc., Downers Grove, IL, USA), showed a background of p3% (probe sensitivity, 100 with 95% confidence limits of 80.5-100% and specificity, 100 with 95% confidence limits of 71.5-100%). Taken together, the normal cutoff for negativity in interphase nuclei for the ELL/MLLT1 probe set was set at p3%.
In our series of 12 adult patients with t(11;19) acute leukemia, the ELL and MLLT1 probes showed perfect translocation breakpoint differentiation, based on their respective cytogenetic and pathological characterization. Analysis of the ELL-positive AML patients with the MLL probe showed the expected abnormal interphase signal pattern (1O1G1Fusion), confirming MLL gene rearrangement and an MLL breakpoint within the common breakpoint cluster region ( Table 1 ). The probe construction yields this interphase signal pattern when the breakpoint within the MLL gene falls within or near exons 6-8 (www.Vysis.com). Additionally, two pediatric ALL specimens were analyzed with the probe set and both showed the expected MLLT1 gene rearrangement. More recently, the distinction between the possible MLL gene translocation partners has been demonstrated by both polymerase chain reaction (PCR) and microarray techniques. 8 Unfortunately, owing to the lack of available residual material, PCR confirmation of the 19p genes involved was not performed for these patients.
In our series, two of 12 (16.6%) adult AML patients with t(11;19) had an MLLT1 gene rearrangement with the corresponding 19p13.3 breakpoint. The MLL interphase FISH pattern for one of these two patients showed a variant MLL interphase pattern, 2F1G, indicating a breakpoint within or near the first exon of the MLL gene or possibly upstream of the MLL gene. The significance of this unusual breakpoint is unknown, and analysis of additional patients is required to determine if those with AML and MLLT1 gene rearrangements routinely or more often have a different MLL gene breakpoint and if these unusual cases are detected by other molecular approaches. It is interesting to speculate whether this difference could potentially contribute to a myeloid disease presentation in adults. Clearly, based on review from the literature 5, 6 and the current study, the majority of adult t(11;19) AML patients have the ELL gene involved in the translocation with 11q; however, based on our limited series and an independent study of adults with acute leukemia, 8 a small, but significant subset of adults with t(11;19) and AML appear to have an MLLT1 gene rearrangement, indicating further clinical and biological evaluation of adult patients with these translocations is warranted. 
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The ELL/MLLT1 dual-color assay described herein entails co-hybridization of probes for the ELL and MLLT1 gene regions, each labeled in a different fluorochrome to allow differentiation between genes involved in 11q;19p chromosome translocations in interphase or metaphase cells. In t(11;19) acute leukemia cases, gain of a signal easily pinpoints the specific translocation breakpoint to either 19p13.1 or 19p13.3 and 11q23. In the re-evaluation of our own cases in light of the FISH data, the 19p breakpoints were re-assigned in two patients, underscoring a certain degree of difficulty in determining the precise 19p breakpoint in acute leukemia specimens in the context of a clinical cytogenetics laboratory. Furthermore, we speculate that the ELL/MLLT1 probe set should detect other 19p translocations that involve these genes with partners other than MLL. Accurate molecular classification of leukemia is becoming more important as targeted therapies are developed and diseases are further sub-classified based on the presence of particular genetic mutations. Distinction of the correct breakpoint, and the gene involved on 19p, is a worthy goal for diagnosis of patients with these cytogenetic aberrations.
Philadelphia chromosome unmasked as a secondary genetic change in acute myeloid leukemia on imatinib treatment The Philadelphia chromosome (Ph), the cytogenetic hallmark of chronic myelogenous leukemia (CML) encodes p210 BCR-ABL fusion protein with enhanced tyrosine kinase activity. In vitro and animal model studies confirm the primary pathogenic role of p210 BCR-ABL fusion protein in the initiation and maintenance of CML, and this has led to the successful development of kinase inhibitors such as imatinib in the control of the disease. In contrast, Ph chromosome-positive acute leukemia poses a biologic and clinical challenge given the difficulty in distinguishing de novo acute leukemia from blast-crisis presentation of CML, the role of p210 BCR-ABL versus p190
BCR-ABL protein kinases, and the variability of outcome and experience with use of imatinib. We describe a patient who presented with Ph þ acute myeloid leukemia (AML) with two additional clonal markers, in which imatinib unmasked the Ph chromosome as a secondary genetic change.
A 49-year-old lady was admitted for pallor, weight loss and poor appetite. There was no splenomegaly. Hemoglobin was 3.6 g/dl, platelet 295 000/ml and white blood cells 137 Â 10 9 /l. Peripheral blood showed 65% blasts, 14% neutrophils and 7% myeloid precursors. There was no basophilia. Marrow aspirate confirmed AML with 74% blasts and chromosome analysis showed 45,XX,inv(3)(q21q26),À7,t(9;22)(q34; q11.2) [12] . Reverse transcriptase-polymerase chain reaction (RT-PCR) for BCR-ABL showed only the e1a2 transcripts. Fluorescence in situ hybridization (FISH) analysis of 300 marrow cells using dual fusion translocation probes (D-FISH, Vysis, Downers Grove, IL, USA) 1 showed 83% were positive for BCR-ABL. The patient failed two cycles of AML induction chemotherapy using daunorubicin and cytarabine with persistent leukemia and 78% of marrow cells positive for BCR-ABL by FISH. Imatinib 600 mg daily was then started, bone marrow examination 6 weeks later still showed 15% blasts. FISH studies showed no BCR-ABL-positive cells (sensitivity 0.3%); however, 39% marrow cells, including segmented neutrophils, were positive for monosomy 7 using the a-satellite sequences in the centromeric region of chromosome 7 (CEP7,D7Z1, Vysis). Cytogenetics showed poor growth, but one metaphase showed 45,XX,inv(3)(q21q26),À7. Taken together, these studies provide evidence that the Ph þ translocation is secondarily acquired in an initial clone characterized by inv(3)(q21q26),À7, which was unmasked after the imatinib treatment. After 5 months of imatinib
